As machine capability shifts from passive responses to autonomous operation, the concept of singularity – coined in the academic realm and adopted by science fiction – is one every professional needs to know.
Opinion: AI has torn up the rule book of competitive advantage, argues Kim Teo, co-founder and CEO of me&u. Founders will need to focus on AI-proofing their moats instead.
Exclusive: In the lead-up to its IPO, Anthropic President and co-founder Daniela Amodei talks to Forbes Australia about containing its new model, Mythos, and why the frontier lab is anchoring in Australia.
Opinion: As politicians and economists search for answers to Australia’s productivity woes, Lauren Ryder argues the real problem may be how we measure work in a modern economy. Every few months, a new set of productivity figures lands and the political handwringing begins. We are told that GDP per-hour-worked has flatlined and that multifactor productivity is declining. […]
As many Australian business owners gear up for retirement, uncertainty around the Budget’s CGT changes may harm succession plans and retirement outcomes
Airtree and the NRF led a $158 million round in March that valued Advanced Navigation at over $1 billion. Documents lodged with ASIC reveal a sharp rise in revenue and a fall in losses in the lead up to that unicorn round.
Australian Retirement Trust has backed Gilmour Space Technologies, extending the startup’s $217 million Series E which valued it at over $1 billion.
Maternal monitoring platform Oli has closed a $6.5 million Series A3 round – drawing funds from Scale Investors, the University of Sydney, and Clare Ventures – to address postpartum hemorrhage, which globally takes the life of one mother every 8 minutes.
Alex Zaccaria, the founder of unicorn Linktree, is among the Australian founders aggrieved by proposed changes to the capital gains rate. He believes the Government is well intentioned, but that the result will be more and more Australian startups shifting their centre of gravity to the US.
Injectable peptides are booming across wellness and biohacking circles, but the science and regulatory oversight are struggling to keep pace, writes Dr Sophia Moscovis.